Q-omics provides the consensus-scored LRRC26 profile across patient tissues and cancer cell-line models. LRRC26 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LRRC26 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, LRRC26 RNA expression shows 13,714 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, HNSC, and THYM as cancer lineages where LRRC26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC26 survival associations across molecular data types. LRRC26 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC26 RNA expression–survival associations across cancer types. High LRRC26 expression shows unfavorable associations in UCS and ESCA, but favorable associations in UCEC, STAD, COAD and DLBC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LRRC26 RNA expression.
This table summarizes LRRC26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC26 shows lower tumor expression in HNSC and higher tumor expression in UCEC, BLCA, LIHC, BRCA and PRAD. The HNSC box plot shows higher LRRC26 RNA expression in normal versus tumor tissue (log2 FC = −1.401, t-test p < 0.001).
This table shows molecular features associated with LRRC26 in patient tissues and cancer cell lines. In patient samples, LRRC26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
